


Diaveridine

Cat. No.:	HY-B1902		
CAS No.:	5355-16-8		
Molecular Formula:	C ₁₃ H ₁₆ N ₄ O ₂		
Molecular Weight:	260.29		
Target:	Antifolate; Bacterial		
Pathway:	Cell Cycle/DNA Damage; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 33.33 mg/mL (128.05 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	3.8419 mL	19.2093 mL	38.4187 mL
		5 mM	0.7684 mL	3.8419 mL	7.6837 mL
10 mM		0.3842 mL	1.9209 mL	3.8419 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.60 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	Diaveridine (EGIS-5645) is a dihydrofolate reductase (DHFR) inhibitor with a K _i of 11.5 nM for the wild type DHFR and also an antibacterial agent.
IC₅₀ & Target	Ki: 11.5 nM (DHFR) ^[1] Bacterial ^[2]
In Vitro	Diaveridine is a dihydrofolate reductase (DHFR) inhibitor with a K _i of 11.5 nM for the wild type DHFR and also an antibacterial

agent^[1]. Treatments with Diaveridine for 90 min have a strong bactericidal effect on *S. typhimurium* TA1535, and no bacterial growth is observed at 10 µg/mL or more. Without metabolic activation, treatment with Diaveridine for 48 h, but not 24 h, causes a dose-dependent, significant increase in the frequency of aberrant metaphases. At 100 µg/mL, 60% of the metaphases contain chromosome aberrations^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The sperm abnormality of the Diaveridine (DVD) treatment groups at all dose levels (Diaveridine, 128 to 512 mg/kg) shows no significant differences compare with the negative control group. There are no significant differences of micronucleus between the negative control group and the Diaveridine treatment groups (Diaveridine, 128 to 512 mg/kg). The chromosome aberration of the Diaveridine treatment groups at all dose levels and the negative control group are significantly lower than those in the positive control group treated with cyclophosphamide ($P < 0.05$), indicating that Diaveridine at the doses studied does not cause abnormal chromosome aberration. The results demonstrate that the Diaveridine administration does not produce significant changes in the ratio of organ-to-body weight, compare with the negative control group in the end period of the study^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay^[2]

Cells are cultured at 37°C in a humidified atmosphere of 5% CO₂ in air. The growth medium is Eagle's MEM supplemented with 10% fetal bovine serum. In the experiment without metabolic activation, the cells are treated for 24 or 48 h continuously without a medium change. In the experiment with metabolic activation, the cells are pulse treated with test compounds (including Diaveridine) at varying doses for 6 h and incubated for 18 h in fresh culture medium. Breakage type chromatid aberrations, exchange type chromatid aberrations, breakage type chromosome aberrations, and exchange type chromosome aberrations are scored. Gaps are also counted. Mitotic index is determined from scoring 2000 cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

^[3]Fifty male ICR mice, weighing 25 to 35 g, are assigned to five groups randomly with 10 mice in each group. Mice in the experiment groups receive Diaveridine (DVD) via IG at ed 128 mg/kg (low doses), 256 mg/kg (medium doses), and 512 mg/kg (high doses) body weight for 5 consecutive days, respectively. Mice in negative and positive control groups receive IG 1% CMC-Na solvent and 40 mg/kg body weight of cyclophosphamide, respectively. The testing groups are administered 0.2 mL/10 g Diaveridine (mixed with 1% of CMC-Na, to obtain the concentration of 2 mg/mL.) body weight, once a day, for 5 days. The behavioral changes are recorded on the daily basis^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sirichaiwat C et al. Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from *Plasmodium falciparum*. *J Med Chem* 47:345-54 (2004).

[2]. Ono T, et al. The genotoxicity of diaveridine and trimethoprim. *Environ Toxicol Pharmacol*. 1997 Sep;3(4):297-306.

[3]. Wang J, et al. Acute, mutagenicity, teratogenicity and subchronic oral toxicity studies of diaveridine in rodents. *Environ Toxicol Pharmacol*. 2015 Sep;40(2):660-70.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA